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Abstract
Background:  The purpose of this analysis was to characterize the placebo response in
antimuscarinic drug trials for OAB, based on changes in commonly-used efficacy endpoints.
Methods: Placebo arm data for incontinence episodes, micturitions, voided volume and study
characteristics were extracted from randomized placebo controlled antimuscarinic drug trials in
OAB, from studies identified in a prior meta-analysis, and from a systematic review of more
recently published studies. Relationships between variables were examined using linear regression,
and changes in endpoints were analyzed by a meta-analysis approach. The effect of placebo arm size
and magnitude of placebo response on probability of successful study outcome was analyzed using
an ANOVA model.
Results:  Changes in the placebo arms for all 3 endpoints were substantial and statistically
significant, and highly heterogeneous. There were significant associations between baseline and
change scores for some but not all of the endpoints. More recent studies tended to have more
subjects than earlier studies, and there were positive associations between probability of achieving
statistically significant results and size of the placebo arm. The magnitude of changes in placebo
arms did not appear to influence the likelihood of the study to be statistically significant.
Conclusion: This analysis confirms earlier observation that the placebo response in OAB trials is
substantial and highly heterogeneous. There are multiple potential reasons for this; however, these
could not be explored in this analysis of study-level data. Two approaches may be used in clinical
trials to manage high placebo effect: recruitment of 1) greater numbers of patients and/or 2) more
severely affected patients; however, only the former approach is associated with increased
probability of successful study outcome.
Background
Clinical trials of antimuscarinic drugs in overactive blad-
der (OAB) have noted marked responses in patients
treated with placebo. While this led some to question the
usefulness of treatment interventions [1,2], more recent
reviews have confirmed the clinical benefit of antimus-
carinics in OAB [3,4]. However both of these
metaanalyses also emphasized the modest difference in
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outcome measures between active and placebo arms.
Nabi et al [3] calculated that 41% of subjects allocated to
placebo arms reported symptomatic improvement or
cure, compared with approximately 56% in patients allo-
cated to active treatment. Chapple et al [4] also noted con-
siderable variation in placebo rates between trials.
Despite these observations, the placebo response in drug
trials for OAB has not been well characterized. One paper
reported on study level data in registration trials for drugs
treating lower urinary tract symptoms [5] and another
from patient level data in four pooled studies in stress uri-
nary incontinence [6]. Issues identified with high placebo
response included patient and disease characteristics (e.g.
less severe disease), amount of prior and concomitant
treatment (e.g. pelvic floor training), and types of end-
points (subjective rather than objective). Nonspecific fac-
tors associated with trial participation, such as increased
awareness of voiding habits and interactions with clinical
trial staff were also considered relevant.
The purpose of this analysis was to characterize the pla-
cebo response in antimuscarinic drug trials for OAB,
based on changes in commonly-used efficacy endpoints
of 1) number of micturitions per day, 2) number of incon-
tinence episodes per day and 3) mean voided volume per
micturition. A number of statistical methods were used,
including a meta-analysis to obtain a more precise esti-
mate of the placebo effect based on pooled results from
various studies.
Methods
Data Sources and Study Selection
The search strategy for the selection of randomized clini-
cal trials for the meta-analysis of placebo response is sum-
marized in Figure 1. We selected all placebo-controlled
trials included in a recent comprehensive meta-analysis of
antimuscarinic treatments for OAB [7]. In addition, we
identified any additional trials that had been published in
the 12 months up to July 2008 through a systematic
review of the literature using all major literature databases
for publications reporting randomized, double-blinded,
placebo-controlled trials for individuals diagnosed with
OAB, and that were not included in the recent meta-anal-
ysis [7]. Data collection, selection, extraction and record-
ing were in accordance with Cochrane Reviews Guidelines
Search Strategy for Selection of Randomized Clinical Trials for Meta-Analysis. Figure 1
Search Strategy for Selection of Randomized Clinical Trials for Meta-Analysis.BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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[8]. Searches included combinations of the terms overac-
tive bladder, urge urinary incontinence, randomized,
double-blind, placebo-controlled, and names of com-
mon antimuscarinic medications. In addition, searches
included the abstracts from several major conferences.
There were seven drugs included in this review
(darifenacin, fesoterodine, oxybutynin, propiverine, solif-
enacin, tolterodine, and trospium).
For inclusion in this analysis, publications had to meet
the following eligibility criteria; 1) the study was a double-
blind randomized placebo-controlled trial of an antimus-
carinic medication in patients with OAB; 2) the total
number of patients assigned to placebo was reported, and
3) the study reported one or more of the following end-
points: number of incontinence episodes per day, number
of micturitions per day, and/or volume voided per mictu-
rition. Additional information was requested through
direct contact with study authors for abstracts that did not
report some of the above details, or for studies where end-
point data were presented as medians rather than means.
Because of different assumptions about data distribution,
only studies reporting mean data were included.
Study Procedure (Data Extraction)
After the publications were obtained, two of the authors
(SL and PG) independently determined the eligibility of
each publication by applying the above criteria. If data
were reported in more than one publication, only the pri-
mary publication was included in this analysis. Study
characteristics (year of publication, patient numbers, ages,
duration of treatment, diary details), and baseline, end-
point, and change from baseline of the above endpoints,
associated estimates of variability (if reported) and statis-
tical power were extracted by one author and entered into
Microsoft Excel. Studies that reported their endpoints as
number of incontinence episodes per week were con-
verted to episode per day, by dividing the values by seven.
Statistical Methods
Summary statistics were calculated for all variables. The
relationship between baseline and change in endpoints,
and study size versus year of publication, was assessed
using linear regression. The probability of success (achiev-
ing statistical significance) as a function of the size of the
placebo arm was estimated using logistic regression. The
relationship between year of publication and baseline and
change in endpoints was assessed using Spearman regres-
sion. A meta-analysis was conducted to pool the results of
change from baseline data for each of the 3 endpoints
using Comprehensive Meta-analysis software version 2.0.
For each endpoint, change from baseline was summarized
as non-standardized (weighted) means using inverse var-
iance weighting. Point estimates and 95% confidence
intervals (CIs) were computed with both random effects
(Der Simmonian and Laird method) and fixed effects
models. The null hypothesis of homogeneity of response
across studies was tested with the Cochran Q statistic. If
the null hypothesis was rejected, point estimates and 95%
CI were estimated on the basis of random effects model
was presented, otherwise the fixed effects model was pre-
sented. An ANOVA model was used to assess the possibil-
ity that the magnitude of placebo change might influence
the probability of study success, with magnitude of
change in the placebo arms as the dependent variable and
study, success (statistically significant separation between
active and placebo arms) and power of the study (80% or
90%) as independent variables. Statistical testing was car-
ried out at the 5% level of significance (two-sided tests).
Results
Trial characteristics
Thirty-four publications which included a placebo arm
were identified in the Chapple meta-analysis [7]. The sys-
tematic literature review over the most recent 12 months
identified 2 additional studies [9,10]. The 36 studies were
identified that met acceptance criteria, and these are listed
in Table 1[9-44]. The most commonly published OAB tri-
als were for tolterodine (n = 15), oxybutynin (n = 8),
propiverine (n = 5) and solifenacin (n = 5) (note: several
studies included more than one active arm). The mean age
of patients enrolled in the placebo arms was 58.9 years.
All studies included adult subjects but four studies specif-
ically targeted elderly subjects [12,19,21,30]. Median
study duration was 12 weeks (range 2–12 weeks). The
mean number of patients in the placebo arms of the trials
was 164 (range 13–508).
Size of placebo arms tended to increase in more recent
studies (r = 0.52; Figure 2A). There were positive associa-
tions between the probability of studies reporting statisti-
cally successful outcomes and the size of the placebo arm
for all endpoints (Figure 2B). This was statistically signifi-
cant for incontinence episodes (p = 0.03), but not for mic-
turitions/day (p = 0.17) or mean voided volume (p =
0.58). It was not possible to assess the influence of some
variables on placebo response, either because they were
too homogeneous (e.g. study duration was 12 weeks in
22/36 studies), or because they were not reported (e.g.
diary duration in only half of the studies).
Incontinence episodes/day
Baseline mean (SD) incontinence episodes/day in sub-
jects randomized to placebo were 3.16 (1.00). At study
endpoint, mean (SD) incontinence episodes/day were
reduced by 1.16 (0.46). The change in incontinence epi-
sodes/day was highly associated with baseline values (r =
0.69; Figure 3A). Although there was no relationship
between baseline incontinence episodes and year of pub-
lication (r = -0.03), there was a modest positive relation-
ship between change in incontinence episodes and year of
publication (r = 0.39, p = 0.10). There was a negative cor-BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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Table 1: Results for placebo treatments in the studies included in the meta-analysis.
Author, 
date 
[reference]
Placebo Duration 
(wks)
Mean micturitions/day Mean incontinence episodes/day Mean volume voided per 
micturition (mL)
n BL EOT CFBL BL EOT CFBL BL EOT CFBL
Abrams, 1998 
[11]
57 12 11.7 NR -1.6 3.3 NR -0.9 157 NR 6
Burgio, 1998 
[12]
65 8 NR NR NR 2.2 1.2 -1.03 NR NR NR
Cardozo, 
2004 [13]
301 12 NR NR -1.59 NR NR -1.25 NR NR 10.67
Chapple, 2004 
[14]
38 4 11.1 10.1 -1.03 1.7 1.4 -0.29 134.7 144.4 9.7
Chapple, 2004 
[15]
267 12 12.2 11 -1.2 2.7 2 -0.76 143.8 151.2 7.4
Chapple, 2007 
[16]
285 12 12 10.9 -1.02 3.7 2.5 -1.2 150.2 159.9 9.77
Dmochowski, 
2002 [17]
132 12 NR NR -1.7 NR NR NR NR NR NR
Dmochowski, 
2003 [18]
117 12 12.3 10.9 -1.4 5 2.9 -2.1 175 182 9
Dmochowski, 
2008 [9]
284 12 12.9 11.1 -1.8 4 2.4 -1.6 151.8 169.6 17.8
Dorschner, 
2003 [19]
49 4 7.1 6.5 -0.6 0.4 0.2 -0.1 187 178 -8.4
Drutz, 1999 
[20]
56 12 11.4 10.3 -1.1 3.6 2.6 -1 160 172 12
Halaska, 1994 
[21]
47 4 NR NR NR NR NR NR 195 221 26
Herschorn, 
2007 [22]
204 12 11.8 10.1 -1.7 3.2 1.8 -1.4 NR NR NR
Homma, 2003 
[23]
122 12 11.1 9.6 -1.5 2.7 1.6 -1.09 130.7 145.8 15.2
Jacquetin, 
2001 [24]
51 4 11.7 10.5 -1.2 2.4 NR -0.4 148 155 7
Junemann, 
2000 [25]
60 3 NR NR -1.9 NR NR NR NR NR NR
Junemann, 
2006 [26]
202 4.57 13.4 10.3 -3.07 3.5 1.7 -1.78 144.2 173.5 29.3
Khullar, 2004 
[27]
285 8 10.6 9.3 -1.3 3.1 NR -1.14 167 185.9 18.9BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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Lee 2006, [28] 79 12 13 10.4 -2.58 NR NR NR NR NR NR
Madersbacher, 
1999 [29]
72 4 11.5 10.5 -1 NR NR NR NR NR NR
Malone-Lee, 
2001 [30]
43 4 9.9 10.3 0.4 5.1 4.4 -0.7 152 162 10
Malone-Lee, 
2002 [31]
73 12 NR NR NR NR NR NR NR NR 15.91
Millard, 1999 
[32]
64 12 11.3 9.9 -1.4 3.5 2.2 -1.3 158 168 10
Nitti, 2007 
[33]
274 12 12.2 11.1 -1.08 3.7 2.7 -0.96 159 167.4 8.38
Rackley, 2006 
[34]
421 12 12.6 NR NR 0.72 NR NR 140.1 NR NR
Rentzhog, 
1998 [35]
13 2 10.2 NR -0.3 4.1 NR -0.4 NR NR NR
Robinson, 
2007 [36]
61 6 11.9 10.1 -1.81 2.9 2.2 -0.66 145.5 156.9 11.4
Rogers, 2008 
[37]
211 12 12.5 10.3 -2.2 2.2 0.8 -1.3 NR NR NR
Rudy, 2006 
[38]
329 12 13.2 11.4 -1.76 NR NR NR 154.6 164.1 9.44
Staskin, 2007 
[10]
303 12 12.7 10.8 -1.99 4.1 2.2 -1.93 155.9 174.8 18.89
Thuroff, 1991 
[39]
27 4 NR NR -0.3 NR NR NR NR NR NR
Uchida, 2002 
[40]
53 4 10.9 9.9 -1 2.3 1 -1.3 196 202 6
van 
Kerrebroeck, 
2001 [41]
508 12 11.3 9.1 -2.2 3.3 2.3 -0.99 136 150 14
Wang, 2006 
[42]
21 12 NR NR NR NR NR NR 350 340 10
Yamaguchi, 
2007 [43]
405 12 11.4 10.3 -0.94 2 1.3 -0.72 152.8 164.5 11.67
Zinner, 2004 
[44]
256 12 12.9 11.6 -1.29 4.3 2.4 -1.9 156.6 164.3 7.7
BL: Baseline
EOT: End of treatment
CFBL: Change from baseline
NR: Not reported
Table 1: Results for placebo treatments in the studies included in the meta-analysis. (Continued)BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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Relationship of the size of placebo arm with (A) the year of publication (Panel A) and the probability of successful study out- come (Panel B) for three commonly used endpoints Figure 2
Relationship of the size of placebo arm with (A) the year of publication (Panel A) and the probability of suc-
cessful study outcome (Panel B) for three commonly used endpoints.
Incontinence episodes/day. Figure 3
Incontinence episodes/day. Panel A: Relationship between baseline and change scores. Panel B: Funnel plot from meta-anal-
ysis.  BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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relation between study size and change in incontinence
episodes/day (r = -0.25).
Point estimates (95%CI) from the meta-analysis of
change from baseline data were -1.09 (-1.17, -1.02) using
a fixed effect model, and -1.15 (-1.34, -0.96) using a ran-
dom effects model. The forest plot is shown in Figure 4,
upper panel. Both results were highly statistically signifi-
cant (p < 0.0001). Considerable heterogeneity in the data
set was suggested by the high Q-value (85.2, df = 16, p <
0.0001), indicating that a random effects model was a
more appropriate analytical approach. The high degree of
data heterogeneity was also evident on the funnel plot
(Figure 3B). Analysis of the relationship between the mag-
nitude of placebo response and successful study outcome
and power showed no statistical difference (p = 0.80 and
0.97 respectively).
Mean micturitions per day
Baseline mean (SD) micturitions/day in subjects rand-
omized to placebo were 11.8 (0.9). At study endpoint,
mean (SD) micturitions/day were reduced by 1.4 (0.7).
The change in mean micturitions/day was highly associ-
ated with baseline values (r = 0.62; Figure 5A). There was
a modest positive relationship between baseline micturi-
tions/day and year of publication (r = 0.34, p = 0.09),
however there was no relationship between change in
micturitions/day and year of publication (r = 0.02). There
was a modest negative correlation between study size and
change in micturitions/day (r = -0.21).
Point estimates (95% CI) from the meta-analysis of
change from baseline data were -1.29 (-1.38, -1.12) using
a fixed effect model, and -1.27 (-1.51, -1.03) using a ran-
dom effects model. The forest plot is shown in Figure 4,
center panel. Both results were highly statistically signifi-
cant (p < 0.0001). Considerable heterogeneity in the data
set was suggested by the high Q-value (107.0, df = 17, p <
0.0001), indicating that a random effects model was a
more appropriate analytical approach. The high degree of
data heterogeneity was also evident on the funnel plot
(Figure 5B). Analysis of the relationship between the mag-
nitude of placebo response and successful study outcome
and power showed no statistical difference (p = 0.93 and
0.21, respectively).
Mean voided volume
Baseline mean (SD) mean voided volume was 163.1
(42.9) mL. After placebo treatment, mean voided volume
was increased by 12.5 (5.9) mL. There was no relationship
between baseline and change in mean voided volume (r =
0.06; Figure 6A). There was a modest negative relation-
ship between baseline mean voided volume and year of
publication (r = -0.23, p = 0.32), however there was no
relationship between change in mean voided volume and
year of publication (r = 0.06). There was no relationship
between study size and change in mean voided volume (r
= -0.07).
Point estimates (95% CI) from the meta-analysis of
change from baseline data were 18.6 (18.3, 18.9) using a
fixed effect model, and 12.4 (9.3, 15.5) using a random
effects model. The forest plot is shown in Figure 4, lower
panel. Both results were highly statistically significant (p <
0.0001). Considerable heterogeneity in the data set was
suggested by the high Q-value (91.0, df = 14, p < 0.0001),
indicating that a random effects model was a more appro-
priate analytical approach. The high degree of data heter-
ogeneity was also evident on the funnel plot (Figure 6B).
Analysis of the relationship between the magnitude of
placebo response and successful study outcome and
power showed no statistical difference (p = 0.26 and 0.50
respectively).
Interrelationship of endpoints
Changes in all 3 endpoints showed were correlated with
one another and showed moderate levels of association.
Change in incontinence episodes was positively associ-
ated with change in micturitions (r = 0.49). As would be
expected based on unchanged daily urine output, the
change in mean voided volume was negatively associated
with change in incontinence episodes (r = -0.38) and
change in micturitions (r = -0.61).
Discussion
The main findings of this analysis are that for three com-
monly published endpoints in OAB studies, changes in
the placebo arms were substantial and statistically signifi-
cant. A high degree of heterogeneity was noted for all end-
points. There were significant associations between
baseline and change scores for some but not all of the end-
points. More recent studies tended to be larger than earlier
studies, and there were positive associations between
probability of achieving statistically significant results and
size of the placebo arm. The magnitude of changes in pla-
cebo arms did not appear to influence the likelihood of
the study to be statistically different from active treatment.
This analysis confirms earlier observations that the pla-
cebo response in OAB trials is substantial [3,4]. In a meta-
analysis of placebo responses across different disorders,
drug trials in urogenital disorders had the highest placebo
response [45]. This may be an underlying consequence of
urological disorders in general, rather than related to type
of intervention, as high placebo response rates have also
been reported in trials of non-pharmacological manage-
ment of incontinence. For example, in a trial of pelvic
floor muscle training for stress urinary incontinence, a
64% response rate was reported for the sham (placebo)
intervention arm [46]. Urological disorders are generallyBMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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Forest plots form the meta-analysis of commonly used endpoints in OAB trials. Figure 4
 Forest plots form the meta-analysis of commonly used endpoints in OAB trials.BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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Mean micturitions/day. Figure 5
Mean micturitions/day. Panel A: Relationship between baseline and change scores. Panel B: Funnel plot from meta-analysis.  
Mean voided volume/day. Figure 6
Mean voided volume/day. Panel A: Relationship between baseline and change scores. Panel B: Funnel plot from meta-analy-
sis.  BMC Medical Research Methodology 2009, 9:55 http://www.biomedcentral.com/1471-2288/9/55
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kept private by the patients and a majority of people with
UI do not seek help despite poor quality of life (i.e., per-
ceived lack of self-control, limited daily activities for fear
of an "accident"). [47] As a result, in routine clinical prac-
tice, there may not be a lot of patient-level basic knowl-
edge about these urological conditions. However, when
participating in a clinical research trial for a urologic prob-
lem, there is a much greater enhancement in patient
knowledge and awareness of their disorder than it would
be for a condition (e.g., cardiovascular or metabolic) that
is more openly discussed.
A meta-analysis approach was used in order to obtain a
more precise estimate of the placebo effect based on
pooled results from various studies. Both fixed and ran-
dom effects models were tested, to provide an indication
on the variability of the results. Because the meta-analysis
revealed a high degree of heterogeneity for all three end-
points, a random effects approach was used in this analy-
sis. Egger et al [48] has identified a number of potential
causes of heterogeneity. Factors that might contribute to
heterogeneity in OAB studies include the nature of the
population studied (i.e. the presence of mixed types of
incontinence), size of the studies (ranging from 13 to 508
subjects/arm), use of both subjective and objective end-
points, and/or changes in study methodology and types of
patients recruited into OAB trials performed over almost
2 decades. We confirm earlier observations that subjective
endpoints may be an important contributor to heteroge-
neity [5,6]. In OAB trials, a positive correlation of the pla-
cebo response with baseline severity was seen for the
changes in the endpoints of micturitions and inconti-
nence episodes but was not seen for the mean voided vol-
ume.
We were not able to explore the role of other potentially
important variable on placebo responses. Because this
analysis was performed on study level data, it is not possi-
ble to assess the effects of patient level characteristics (e.g.
age, gender), or other aspects of design (visit frequency or
study location) on responses. It is unclear how important
study duration is to placebo responses. Because almost all
antimuscarinic OAB studies are 12 weeks long, it is not
possible to assess the effects of longer or shorter duration
on placebo responses. Finally, the type of diary (paper or
electronic) and the duration of recall was not reported by
a majority of studies. In particular, the length of time over
which patients have to recall subjective endpoint data
may be important, with longer durations being associated
with greater potential for error.
This analysis confirms that the placebo response in
antimuscarinic drug trials for OAB is substantial, and
demonstrates high levels of heterogeneity. The substantial
placebo response has been noted in treatment trials for
other urological disorders, with both drug and non-drug
interventions, and may reflect nonspecific effects related
to use of a diary, behavioral training, etc, and/or to the use
of subjective endpoints. Therefore, in essence, the placebo
effect seen in these trials is ascribable to all non-drug
aspects of the trial, in addition to treatment with placebo.
Two approaches have been attempted to manage the pla-
cebo response- (1) to enroll more severely affected
patients in more recent trials (as indicated by the positive
association between year of publication and baseline
symptom severity); and (2) to enroll larger numbers of
subjects. Enrolling more severely affected patients appears
to be counterproductive however, as any increase in
changes in active treated arms may be offset with larger
responses in the placebo arms. Furthermore, our analysis
has shown that the probability of study success was unre-
lated to the magnitude of placebo response in any of the
endpoints studied. Using increased sample sizes may have
been more effective in ensuring successful study outcome,
as demonstrated by the positive associations between
these 2 variables (Figure 2B). However this association
appears to be greatest for the subjective endpoints, and
more modest for the objective endpoint.
Conclusion
This analysis confirms earlier observations of substantial
heterogeneity in placebo responses in antimuscarinic
drug trials for OAB. More recent clinical trials have tried to
address this by recruiting greater numbers of subjects and/
or more severely affected patients; however, only the
former approach is associated with increased probability
of successful study outcome. Alternative approaches to
managing the large and heterogeneous placebo response
in OAB drug trials in the future might be to develop and
validate more objective endpoints for OAB trials, charac-
terize more drug-responsive subpopulations of patients,
and/or to explore different trial designs that can reduce
population heterogeneity (e.g. relapse prevention).
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